Sanofi (SNY)
The price, the headline numbers and the latest news, in one place.
Sanofi (SNY) Stock Price, Analysis & Data
| Bid | 37.02 |
| Market Cap | 103B |
| Revenue (ttm) | 48.9B |
| Net Income (ttm) | 3.94B |
| 0.28 | |
| 1.88 | |
| 22.79 | |
| 7.9 | |
| P/B (ttm) | 1.29 |
| P/S (ttm) | 2.10 |
| Earnings Date | Oct 30, 2026 |
| Ask | 49.12 |
| Volume | 168,842 |
| Avg. Volume (20D) | 3,314,954 |
| Open | 43.09 |
| Previous Close | 43.16 |
| Day's Range | 43.02 - 43.46 |
| 52-Week Range | 40.89 - 52.68 |
| Analyst | Buy |
| Price Target | 54.5 (25.46%) |
| Dividends | $2.42 (5.61%) |
| Ex-Dividend Date | May 4, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a ...
Financial Performance
In 2025, Sanofi's revenue was 46.72B, an increase of 5.49% compared to the previous year's 44.29B. Earnings were 7.81B, an increase of 40.52%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for SNY stock is "Buy". The 12-month stock price forecast is 54.5, which is upside of 25.46% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $12.3B misses estimates by $0, with 14.58% YoY growth.
- EPS of 1.2 exceeds estimates by 0.06, with 31.87% YoY growth.
Analysts project revenue of ... Upgrade
